uniQure N.V.
NASDAQ:QUREBiotechnology
-$1.13 today
- Market cap
- $1.42B
- Beta
- 1.00
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$3.33
Volume 1.16M
Average 1.75M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
uniQure N.V.
NASDAQ:QURE
Intrinsic Alpha fair value
Locked
Current Price
$20.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -46.7% | +118.5% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -46.7% over three years. Forward estimates point to Revenue at +118.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | $1.64B | $16.08 | Not rated | -4.6 | -44.77% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.56% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +3.68% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | $7.64 | Not rated | -1.5 | -33.95% |
Neurogene Inc. NASDAQ:NGNE | $378.15M | $23.93 | Not rated | -7.1 | +12.40% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $252.48M | $2.30 | Not rated | -1.7 | -25.70% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -60.64% |
Continue the stock analysis
Jump to another research area for this company.